Panel recommends Vioxx return to market in Canada

A medical advisory panel in Canada recommended Merck's painkiller Vioxx be allowed back on the market despite some cardiovascular risk, and also said Pfizer's Celebrex should remain on the market. The panel recommended Pfizer's other arthritis drug, Bextra, also a Cox-2 inhibitor, be kept off the market, and said ibuprofen pain relievers, currently sold OTC, should be subject to restrictions. Health Canada must now decide whether to accept the panel's recommendations.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX